1
|
Horinouchi H, Goldman J, Cho B, Tomasini P, Dunbar M, Hoffman D, Parikh A, Blot V, Camidge D. 387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
2
|
Deakin C, De Stavola B, Littlejohn G, Griffiths H, Ciciriello S, Youssef P, Mathers D, Bird P, Smith T, Osullivan C, Freeman T, Segelov D, Hoffman D, Seaman S. POS0691 EMULATING A TARGET TRIAL OF ADALIMUMAB VERSUS TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A COMPARATIVE EFFECTIVENESS ANALYSIS USING THE OPAL REAL-WORLD DATASET. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThere is increasing recognition of the complementary role for real-world evidence (RWE) in health care and regulatory decision-making (1). However, careful analysis is required when drugs are compared using observational data to account for differences between treatment groups. Electronic medical records (EMR) are an important source of real-world data (RWD), but outcomes are often recorded incompletely.We emulated a target trial of adalimumab (ADA) versus tofacitinib (TOF) in patients with rheumatoid arthritis (RA) using the OPAL dataset to illustrate the application of methodologies to address the challenges of non-random treatment assignment and incomplete data. The OPAL dataset is derived from EMR of 112 community-based rheumatologists around Australia, where practitioners have discretion to prescribe whichever b/tsDMARD they consider most clinically appropriate.ObjectivesTo estimate the average treatment effect (ATE) of TOF compared to ADA at 3 and 9 months, defined as the difference in mean disease activity score (DAS28CRP), in patients with RA who are new users of a b/tsDMARD. This is equivalent to aiming to estimate the intention-to-treat effect in a randomised controlled trial.MethodsOPAL patients diagnosed with RA were included if they initiated ADA or TOF between 1 October 2015 and 1 April 2021, were new b/tsDMARD users (no prior recorded b/tsDMARD, at least 6 months of prior csDMARD treatment), and had at least 1 component of DAS28CRP recorded at baseline or during follow-up. Data were also extracted on baseline characteristics. Baseline characteristics were DAS28CRP, patient demographics, regional location, disease duration, prescriber characteristics (including gender, experience), prior recorded comorbidities, and prior and concomitant treatment with csDMARDs and oral corticosteroids.We used random forest multiple imputation to impute missing baseline and follow-up DAS28CRP components (2). Stable balancing weights (SBW) were then used to balance the treatment groups in terms of their baseline characteristics, including DAS28CRP (3). For each imputed dataset, the ATE at 3 months was estimated as the difference between the mean outcome in the two treatment groups after balancing (i.e. weighting) the sample, and then these estimates were averaged across the 10 imputed datasets. The ATE at 9 months was estimated similarly. The whole procedure was subsequently performed in 1000 bootstrap samples to estimate a 95% confidence interval (CI) for the ATEs using the percentile method (4).Results842 patients were identified including n=569 treated with ADA and n=273 treated with TOF. After applying the SBW, the maximum difference between the mean of each baseline characteristic in the ADA and TOF groups was less than 0.03% of the corresponding standard deviation in the whole sample, indicating reasonable balance was achieved in this complex dataset. After weighting, mean DAS28CRP reduced from 5.3 at baseline (both ADA and TOF groups) to 2.6 and 2.3 at 3 and 9 months for ADA, and 2.4 and 2.3 at 3 and 9 months for TOF.The estimated ATE was -0.22 (95% CI -0.36, -0.03; p=0.02) at 3 months, indicating a modest but significant reduction in disease activity for patients on TOF. The estimated ATE was -0.03 (95% CI -0.19, 0.1; p=0.56) at 9 months, indicating no difference between groups.ConclusionDAS28CRP was significantly lower at 3 months for patients treated with TOF compared to ADA. However, 3 months of treatment with either drug led to substantive average reductions in mean DAS28CRP, consistent with remission. There was no difference between drugs at 9 months. Future work will estimate a per-protocol effect.References[1]Arlett et al. Clin Pharmacol Ther 2022;111(1):21–3.[2]van Buuren and Groothuis-Oudshoorn J Stat Softw 201145(3):1–67[3]Zubizarreta J Am Stat Assoc 2015;110(511):910–22[4]Bartlett and Hughes Stat Methods Med Res 2020;29(12):3533–46AcknowledgementsThe authors acknowledge the members of OPAL Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.Disclosure of InterestsClaire Deakin: None declared, Bianca De Stavola: None declared, Geoff Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD, Hedley Griffiths Consultant of: AbbVie and Eli Lilly, Sabina Ciciriello: None declared, Peter Youssef Speakers bureau: AbbVie, Novartis, Eli Lilly, David Mathers: None declared, Paul Bird Speakers bureau: Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Novartis, Gilead, Eli Lilly, Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Novartis, Gilead, Eli Lilly, Imaging consulting for Synarc and Boston Imaging Core Lab., Tegan Smith: None declared, Catherine OSullivan: None declared, Tim Freeman: None declared, Dana Segelov: None declared, David Hoffman: None declared, Shaun Seaman: None declared
Collapse
|
3
|
St. Clair B, Hoffman D, Lee R, Montgomery J. A001 MRNA COVID-19 VACCINE ADVERSE EVENTS FOLLOWING IMMUNIZATION: SHOULD YOU RECOMMEND THE SECOND DOSE? Ann Allergy Asthma Immunol 2021. [PMCID: PMC8566862 DOI: 10.1016/j.anai.2021.08.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
4
|
Dwyer D, Gastin P, Hoffman D. The risk of injury in the first five years of an Australian football career – Can it be predicted without using player load? J Sci Med Sport 2021. [DOI: 10.1016/j.jsams.2021.09.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Fried S, Gafner M, Jeddah D, Gosher N, Hoffman D, Ber R, Mayer A, Katorza E. Correlation between 2D and 3D Fetal Brain MRI Biometry and Neurodevelopmental Outcomes in Fetuses with Suspected Microcephaly and Macrocephaly. AJNR Am J Neuroradiol 2021; 42:1878-1883. [PMID: 34385141 DOI: 10.3174/ajnr.a7225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 05/03/2021] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Definitions of fetal microcephaly and macrocephaly are debatable. A better understanding of their long-term prognoses would help guide parental education and counseling. This study aimed to explore the correlation between 2D and 3D fetal brain MR imaging biometry results and the long-term neurodevelopmental outcomes. MATERIALS AND METHODS This analysis is a historical cohort study. Fetal brain biometry was measured on 2D and 3D MR imaging using a volumetric MR imaging semiautomated algorithm. We measured and assessed the following brain structures: the supratentorial brain volume and cerebellar volume and cerebellar volume/supratentorial brain volume ratio, in addition to commonly used 2D brain MR imaging biometric variables, including occipitofrontal diameter, biparietal diameter, and transcerebellar diameter. Microcephaly was defined as ≤ 3rd percentile; and macrocephaly, as ≥ 97th percentile, corresponding to -2 SDs and +2 SDs. The neurodevelopmental outcome of this study cohort was evaluated using the Vineland-II Adaptive Behavior Scales, and the measurements were correlated to the Vineland standard scores. RESULTS A total of 70 fetuses were included. No significant correlation was observed between the Vineland scores and either the supratentorial brain volume, cerebellar volume, or supratentorial brain volume/cerebellar volume ratio in 3D or 2D MR imaging measurements, after correction for multiple comparisons. No differences were found among fetuses with macrocephaly, normocephaly, or microcephaly regarding the median Vineland standard scores. CONCLUSIONS Provided there is normal brain structure on MR imaging, the developmental milestone achievements in early years are unrelated to 2D and 3D fetal brain MR imaging biometry, in the range of measurements depicted in this study.
Collapse
Affiliation(s)
- S Fried
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
- Department of Obstetrics and Gynecology (S.F., E.K.), Sheba Medical Center, Tel-Hashomer, Israel
| | - M Gafner
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
- Department of Pediatrics B (M.G.), Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - D Jeddah
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
| | - N Gosher
- Hadassah Medical School (N.G.), The Hebrew University of Jerusalem, Jerusalem, Israel
| | - D Hoffman
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
| | - R Ber
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
| | - A Mayer
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
- Department of Diagnostic Radiology (A.M.), Sheba Medical Center, Tel-Hashomer, Israel
| | - E Katorza
- From the Sackler School of Medicine (S.F., M.G., D.J., D.H., R.B., A.M., E.K.), Tel-Aviv University, Tel-Aviv, Israel
- Department of Obstetrics and Gynecology (S.F., E.K.), Sheba Medical Center, Tel-Hashomer, Israel
| |
Collapse
|
6
|
Hoffman D, Rodriguez W, Macveigh-Fierro D, Miles J, Muller M. The KSHV ORF20 Protein Interacts with the Viral Processivity Factor ORF59 and Promotes Viral Reactivation. Microbiol Spectr 2021; 9:e0014521. [PMID: 34106579 PMCID: PMC8552657 DOI: 10.1128/spectrum.00145-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Accepted: 05/04/2021] [Indexed: 11/20/2022] Open
Abstract
Upon Kaposi's Sarcoma-associated herpesvirus (KSHV) lytic reactivation, rapid and widespread amplification of viral DNA (vDNA) triggers significant nuclear reorganization. As part of this striking shift in nuclear architecture, viral replication compartments are formed as sites of lytic vDNA production along with remarkable spatial remodeling and the relocalization of cellular and viral proteins. These viral replication compartments house several lytic gene products that coordinate viral gene expression, vDNA replication, and nucleocapsid assembly. The viral proteins and mechanisms that regulate this overhaul of the nuclear landscape during KSHV replication remain largely unknown. KSHV's ORF20 is a widely conserved lytic gene among all herpesviruses, suggesting it may have a fundamental contribution to the progression of herpesviral infection. Here, we utilized a promiscuous biotin ligase proximity labeling method to identify the proximal interactome of ORF20, which includes several replication-associated viral proteins, one of which is ORF59, the KSHV DNA processivity factor. Using coimmunoprecipitation and immunofluorescence assays, we confirmed the interaction between ORF20 and ORF59 and tracked the localization of both proteins to KSHV replication compartments. To further characterize the function of ORF20, we generated an ORF20-deficient KSHV and compared its replicative fitness to that of wild-type virus. Virion production was significantly diminished in the ORF20-deficient virus as observed by supernatant transfer assays. Additionally, we tied this defect in viable virion formation to a reduction in viral late gene expression. Lastly, we observed an overall reduction in vDNA replication in the ORF20-deficient virus, implying a key role for ORF20 in the regulation of lytic replication. Taken together, these results capture the essential role of KSHV ORF20 in progressing viral lytic infection by regulating vDNA replication alongside other crucial lytic proteins within KSHV replication compartments. IMPORTANCE Kaposi's Sarcoma-associated herpesvirus (KSHV) is a herpesvirus that induces lifelong infection, and as such, its lytic replication is carefully controlled to allow for efficient dissemination from its long-term reservoir and for the spread of the virus to new hosts. Viral DNA replication involves many host and viral proteins, coordinating both in time and space to successfully progress through the viral life cycle. Yet, this process is still not fully understood. We investigated the role of the poorly characterized viral protein ORF20, and through proximity labeling, we found that ORF20 interacts with ORF59 in replication compartments and affects DNA replication and subsequent steps of the late viral life cycle. Collectively, these results provide insights into the possible contribution of ORF20 to the complex lytic DNA replication process and suggest that this highly conserved protein may be an important modulator of this key viral mechanism.
Collapse
Affiliation(s)
- D. Hoffman
- Microbiology Department, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| | - W. Rodriguez
- Microbiology Department, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| | - D. Macveigh-Fierro
- Microbiology Department, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| | - J. Miles
- Microbiology Department, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| | - M. Muller
- Microbiology Department, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| |
Collapse
|
7
|
Tymms K, Smith T, Deakin C, Freeman T, Hoffman D, Segelov D, Griffiths H, Ciciriello S, Youssef P, Mathers D, Osullivan C, Littlejohn G. POS1461-HPR THE DEVELOPMENT OF A NOVEL EPRO DELIVERY SYSTEM TO MEASURE PATIENT QUALITY OF LIFE IN ROUTINE CLINICAL CARE: AN ANALYSIS OF 5 YEARS OF EXPERIENCE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Registry studies and clinical trials are increasingly incorporating patient reported outcomes (PROs) to measure the full burden of disease and better measure the efficacy and value of medicines; however, the burden of paper-based surveys, time constraints, and privacy concerns impede the widespread use of PROs in routine clinical care.Objectives:To develop a simple and secure technological solution to incorporate validated PROs into routine clinical care for patients with rheumatic diseases, and to assess the patient response to functional assessment of chronic illness therapy fatigue (FACIT-F), patient health questionnaire-2 (PHQ-2), and healthcare resource utilization (HCRU) questionnaires delivered using this ePRO method.Methods:A novel ePRO questionnaire delivery system was developed by Software4Specialists in partnership with OPAL Rheumatology. Validated PRO questionnaires were sent from the patient’s electronic medical record (Audit4, Software4Specialists) and delivered to the patient’s email address at time intervals specified by the rheumatologist (defaults to quarterly) or completed in the clinic waiting room prior to the consultation using a tablet or the patient’s smart phone (in-practice). Completed questionnaires were encrypted and returned directly to the patient’s Audit4 electronic medical record held on the clinician’s server for review at the next clinical consultation. The link to the PRO questionnaire expired within 28 days if the questionnaire was not completed, and the questionnaires were automatically cancelled if 2 consecutive links expired. This technology was made available to up to 111 rheumatologists located in 42 clinics in 6 states/territories in Australia, and the use of this technology to furnish the clinical consultation was voluntary for clinicians and patients. Deidentified clinical data was extracted from the servers of participating rheumatologists and aggregated across all sites.1 Data collected between April 2016-Dec 2020 was analysed descriptively.Results:Between April 2016-Dec 2020, 99,505 FACIT-F, PHQ-2 and HCRU questionnaires have been delivered to 5,784 patients from 39 of 42 contributing clinics (93%). 85% of questionnaires were delivered via email and 15% in-practice. Overall, 85% of patients completed at least one questionnaire, and of all questionnaires sent, 73% were completed. These rates have remained consistent over time. The completion rates were higher when questionnaires were delivered to patients in-practice compared to email (96% vs 69%). Females were more likely to engage with the questionnaires than males (87% vs 81%), and older patients were slightly more likely to complete all questionnaires delivered. 69% of questionnaires sent via email were completed on the day they were delivered and 94% were completed within 7 days. The median (IQR) number of questionnaires completed per patient was 3 (1,7) and the median (IQR) time since the first questionnaire was completed was 13 months (5,26).Conclusion:The novel Audit4 ePRO delivery system is an effective tool for incorporating PROs into routine clinical care to capture data directly from the patient on the impact of their condition on their quality of life. The data generated provides a unique opportunity to understand the full burden of disease for patients in the real-world setting and the impact of interventions.References:[1]Littlejohn GO, Tymms KE, Smith T, Griffiths HT. Using big data from real-world Australian rheumatology encounters to enhance clinical care and research. Clin Exp Rheum 2020:38(5): 874 -880.Acknowledgements:The authors acknowledge the members of OPAL Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.Disclosure of Interests:Kathleen Tymms: None declared, Tegan Smith: None declared, Claire Deakin: None declared, Tim Freeman: None declared, David Hoffman: None declared, Dana Segelov: None declared, Hedley Griffiths Consultant of: AbbVie, Gilead, Novartis and Lilly., Sabina Ciciriello: None declared, Peter Youssef: None declared, David Mathers: None declared, Catherine OSullivan: None declared, Geoff Littlejohn Consultant of: Over the last 5 years Geoffrey Littlejohn has received educational grants and consulting fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Novartis, Pfizer, Janssen, Sandoz, Sanofi and Seqirus
Collapse
|
8
|
Ponto J, Farkas D, Shimonova M, Yau R, Berger J, Yusupov Y, Hoffman D. Novel Mandibular Full Arch Rehabilitation Using Standardized Prefabricated Hybrid Framework. J Oral Maxillofac Surg 2020. [DOI: 10.1016/j.joms.2020.07.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Grinberg A, Katorza E, Hoffman D, Ber R, Mayer A, Lipitz S. Volumetric MRI Study of the Brain in Fetuses with Intrauterine Cytomegalovirus Infection and Its Correlation to Neurodevelopmental Outcome. AJNR Am J Neuroradiol 2019; 40:353-358. [PMID: 30760462 DOI: 10.3174/ajnr.a5948] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Accepted: 12/01/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE In recent years, effort has been made to study 3D biometry as a method for fetal brain assessment. In this study, we aimed to compare brain volumes of fetuses with cytomegalovirus infection and noninfected controls. Also, we wanted to assess whether there is a correlation to their neurodevelopmental outcome as observed after several years. MATERIALS AND METHODS A retrospective cohort study examined MR imaging brain scans of 42 fetuses (at 30-34 weeks' gestational age) that were diagnosed with intrauterine cytomegalovirus infection. Volumetric measurements of 6 structures were assessed using a semiautomated designated program and were compared with a control group of 50 fetuses. Data collected included prenatal history and MR imaging and sonographic and neurodevelopmental follow-up. RESULTS We found that all brain volumes measured were smaller in the cytomegalovirus-infected group and that there was a correlation between smaller cerebellar volume and lower Vineland II Adaptive Behavior Scales questionnaire scores, especially in the fields of daily living and communication skills. CONCLUSIONS In this study, we found that brain volumes are affected by intrauterine cytomegalovirus infection and that it has a developmental prognostic meaning. Such information, which should be supported by further research, may help clinicians further analyze imaging data to treat and make a better assessment of these fetuses.
Collapse
Affiliation(s)
- A Grinberg
- From the Antenatal Diagnostic Unit (A.G., E.K., D.H., R.B., S.L.), Department of Obstetrics and Gynecology
- Sackler School of Medicine (A.G., E.K., D.H., R.B., A.M., S.L.), Tel Aviv University, Tel Aviv, Israel
| | - E Katorza
- From the Antenatal Diagnostic Unit (A.G., E.K., D.H., R.B., S.L.), Department of Obstetrics and Gynecology
- Sackler School of Medicine (A.G., E.K., D.H., R.B., A.M., S.L.), Tel Aviv University, Tel Aviv, Israel
| | - D Hoffman
- From the Antenatal Diagnostic Unit (A.G., E.K., D.H., R.B., S.L.), Department of Obstetrics and Gynecology
- Sackler School of Medicine (A.G., E.K., D.H., R.B., A.M., S.L.), Tel Aviv University, Tel Aviv, Israel
| | - R Ber
- From the Antenatal Diagnostic Unit (A.G., E.K., D.H., R.B., S.L.), Department of Obstetrics and Gynecology
- Sackler School of Medicine (A.G., E.K., D.H., R.B., A.M., S.L.), Tel Aviv University, Tel Aviv, Israel
| | - A Mayer
- Department of Diagnostic Radiology (A.M.), Chaim Sheba Medical Center, Tel-Hashomer, Israel
- Sackler School of Medicine (A.G., E.K., D.H., R.B., A.M., S.L.), Tel Aviv University, Tel Aviv, Israel
| | - S Lipitz
- From the Antenatal Diagnostic Unit (A.G., E.K., D.H., R.B., S.L.), Department of Obstetrics and Gynecology
- Sackler School of Medicine (A.G., E.K., D.H., R.B., A.M., S.L.), Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
10
|
Peyronnet B, Sussman R, Zhao L, Hoffman D, Armstrong B, Telegrafi S, Granieri M, Palmerola R, Malacarne D, Rosenblum N, Nitti V, Brucker B. Évaluation échographique et traitement de la sténose urétrale de la femme par urétroplastie muqueuse buccale. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Meyer R, Bar-Yosef O, Barzilay E, Hoffman D, Toussia-Cohen S, Zvi E, Achiron R, Katorza E. Neurodevelopmental outcome of fetal isolated ventricular asymmetry without dilation: a cohort study. Ultrasound Obstet Gynecol 2018; 52:467-472. [PMID: 29607569 DOI: 10.1002/uog.19065] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2017] [Revised: 02/10/2018] [Accepted: 03/23/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVE Fetal isolated ventricular asymmetry (IVA) is a relatively common finding in pregnancy, but data regarding its effect on neurodevelopmental outcome are scarce and founded principally on ultrasound-based studies. The purpose of this study was to assess the neurodevelopmental outcome of IVA cases in a magnetic resonance imaging (MRI)-based study. METHODS Cases referred for fetal brain MRI as part of the assessment of IVA without ventriculomegaly (lateral ventricular atrial diameter ≤ 10 mm), identified during routine ultrasound examination, were assessed for possible inclusion. Asymmetry was defined as a difference in width of ≥ 2 mm between the two lateral ventricles. Forty-three cases were included in the study group and compared with a control group of 94 normal cases without IVA. Children were assessed at ages 13-74 months using the Vineland-II Adaptive Behavior Scales (VABS-II). RESULTS VABS-II scores were within normal range. There was no significant difference in composite VABS-II score between the study and control groups (106.5 vs 108.0; P = 0.454). VABS-II scores did not differ between the groups when matched for gender and age at VABS-II interview (109.6 in study group vs 107.8 in control group; P = 0.690). CONCLUSION In cases of IVA without ventriculomegaly on MRI, neurodevelopmental test scores were normal and did not differ from cases without IVA. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- R Meyer
- Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Ramat-Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - O Bar-Yosef
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
- Pediatric Neurology Unit, The Chaim Sheba Medical Center, Ramat-Gan, Israel
| | - E Barzilay
- Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Ramat-Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - D Hoffman
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - S Toussia-Cohen
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - E Zvi
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - R Achiron
- Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Ramat-Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| | - E Katorza
- Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Ramat-Gan, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel
| |
Collapse
|
12
|
Olshaker H, Ber R, Hoffman D, Derazne E, Achiron R, Katorza E. Volumetric Brain MRI Study in Fetuses with Congenital Heart Disease. AJNR Am J Neuroradiol 2018; 39:1164-1169. [PMID: 29674414 DOI: 10.3174/ajnr.a5628] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2017] [Accepted: 02/14/2018] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE It is well-established that a high prevalence of infants with congenital heart defects surviving to childhood have neurodevelopmental abnormalities. The etiology is not clear. In this study, we aimed to find prenatal neuroanatomic changes in fetuses with congenital heart disease to better understand the pathophysiology behind these sequelae. MATERIALS AND METHODS A retrospective study of 46 fetal brain MR imaging scans was performed at a tertiary medical center during a 4-year period. Clinical data were collected from electronic medical charts. Volumes of the supratentorial brain, right hemisphere, left hemisphere, and cerebellum were measured using a semiautomated method and were compared with the normal growth percentiles. RESULTS We found that cerebellar volume and the cerebellar-supratentorial volume ratio were significantly lower among fetuses with congenital heart disease. Supratentorial and hemisphere volumes showed no difference between groups. This difference was not observed in fetuses with septation defects. CONCLUSIONS Fetuses with congenital heart disease have smaller cerebellar volumes than healthy fetuses. Additional research is needed to assess this finding as a radiologic marker for long-term outcome.
Collapse
Affiliation(s)
- H Olshaker
- From the Antenatal Diagnostic Unit (H.O., R.B., D.H., R.A., E.K.), Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel .,Sackler School of Medicine (H.O., R.B., D.H., E.D., R.A., E.K.), Tel Aviv University, Tel Aviv, Israel
| | - R Ber
- From the Antenatal Diagnostic Unit (H.O., R.B., D.H., R.A., E.K.), Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.,Sackler School of Medicine (H.O., R.B., D.H., E.D., R.A., E.K.), Tel Aviv University, Tel Aviv, Israel
| | - D Hoffman
- From the Antenatal Diagnostic Unit (H.O., R.B., D.H., R.A., E.K.), Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.,Sackler School of Medicine (H.O., R.B., D.H., E.D., R.A., E.K.), Tel Aviv University, Tel Aviv, Israel
| | - E Derazne
- Sackler School of Medicine (H.O., R.B., D.H., E.D., R.A., E.K.), Tel Aviv University, Tel Aviv, Israel
| | - R Achiron
- From the Antenatal Diagnostic Unit (H.O., R.B., D.H., R.A., E.K.), Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.,Sackler School of Medicine (H.O., R.B., D.H., E.D., R.A., E.K.), Tel Aviv University, Tel Aviv, Israel
| | - E Katorza
- From the Antenatal Diagnostic Unit (H.O., R.B., D.H., R.A., E.K.), Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.,Sackler School of Medicine (H.O., R.B., D.H., E.D., R.A., E.K.), Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
13
|
Meseko C, Globig A, Ijomanta J, Joannis T, Nwosuh C, Shamaki D, Harder T, Hoffman D, Pohlmann A, Beer M, Mettenleiter T, Starick E. Evidence of exposure of domestic pigs to Highly Pathogenic Avian Influenza H5N1 in Nigeria. Sci Rep 2018; 8:5900. [PMID: 29651056 PMCID: PMC5897404 DOI: 10.1038/s41598-018-24371-6] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Accepted: 03/14/2018] [Indexed: 12/15/2022] Open
Abstract
Avian influenza viruses (AIV) potentially transmit to swine as shown by experiments, where further reassortment may contribute to the generation of pandemic strains. Associated risks of AIV inter-species transmission are greater in countries like Nigeria with recurrent epidemics of highly pathogenic AI (HPAI) in poultry and significant pig population. Analysis of 129 tracheal swab specimens collected from apparently healthy pigs at slaughterhouse during presence of HPAI virus H5N1 in poultry in Nigeria for influenza A by RT-qPCR yielded 43 positive samples. Twenty-two could be determined by clade specific RT-qPCR as belonging to the H5N1 clade 2.3.2.1c and confirmed by partial hemagglutinin (HA) sequence analysis. In addition, 500 swine sera were screened for antibodies against influenza A virus nucleoprotein and H5 HA using competition ELISAs and hemagglutination inhibition (HI) tests. Serologically, 222 (44.4%) and 42 (8.4%) sera were positive for influenza A virus NP and H5 antibodies, respectively. Sera reacted to H5N1 and A/H1N1pdm09 strains by HI suggesting exposure of the Nigerian domestic pig population to these viruses. We report for the first time in Nigeria, exposure of domestic pigs to H5N1 virus. This poses potential public health and pandemic risk due to interspecies transmission of avian and human influenza viruses.
Collapse
Affiliation(s)
- Clement Meseko
- Regional Laboratory for Animal Influenza, National Veterinary Research Institute, Vom, Nigeria.
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany.
- Institute of Epidemiology, Friedrich-Loeffler-Institut, Insel Riems, Germany.
| | - Anja Globig
- Institute of Epidemiology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| | - Jeremiah Ijomanta
- Regional Laboratory for Animal Influenza, National Veterinary Research Institute, Vom, Nigeria
| | - Tony Joannis
- Regional Laboratory for Animal Influenza, National Veterinary Research Institute, Vom, Nigeria
| | - Chika Nwosuh
- Regional Laboratory for Animal Influenza, National Veterinary Research Institute, Vom, Nigeria
| | - David Shamaki
- Regional Laboratory for Animal Influenza, National Veterinary Research Institute, Vom, Nigeria
| | - Timm Harder
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| | - Donata Hoffman
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| | - Anne Pohlmann
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| | - Martin Beer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| | - Thomas Mettenleiter
- Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| | - Elke Starick
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Insel Riems, Germany
| |
Collapse
|
14
|
Morris E, Higuita L, Bhattacharji P, Hoffman D, Azour L, Brusca-Augello G, Shiau M. 3:54 PM Abstract No. 97 Sensitivity and specificity of single inspiratory and expiratory chest radiographs for detection of pneumothorax after CT-guided lung biopsy. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
15
|
Abstract
Background People with critical illness (CI) commonly develop various forms of immune dysfunction, however, there is limited information concerning immune dysfunction in dogs with CI. Hypothesis The immune response in CI dogs differs from that of healthy dogs. Animals Immunologic variables were compared between 14 dogs with CI, defined as APPLEfast score of >20 points, admitted to the University of Missouri Veterinary Health Center Small Animal Clinic Intensive Care Unit and healthy controls (n = 15). Methods Cohort study evaluating constitutive and lipopolysaccharide (LPS)‐stimulated TNF‐α, IL‐6, and IL‐10 production, phagocytosis of opsonized E. coli and respiratory burst capacity after opsonized E. coli or phorbol 12‐myristate 13‐acetate (PMA) stimulation, peripheral blood lymphocyte phenotype, and monocyte expressions of HLA‐DR and TLR‐4. Results Lipopolysaccharide‐stimulated leukocyte TNF‐α (median, Q1, Q3; CI, 49, 49, 120; control, 655, 446, 1174 pg/mL; P = < 0.001), IL‐6 (median, Q1, Q3; CI, 49, 49, 64; control, 100, 49, 166 pg/mL; P = 0.029), and IL‐10 (CI, 49, 49, 56; control, 96, 49, 203 pg/mL; P = 0.014) production and both E. coli (median, Q1, Q3; CI, 60.5, 43, 88.5; control, 86.6, 81, 89.2%; P = 0.047) and PMA (CI, 40, 11.7, 70; control, 93, 83, 97.6%; P = < 0.001)‐stimulated respiratory burst capacity significantly decreased in CI dogs. Percentage of monocytes expressing TLR‐4 greater in the CI dogs (median, Q1, Q3; CI, 46.9, 24.3, 64.2; control, 16.4, 9.4, 26.2%; P = 0.005). Conclusion These findings suggest dogs with CI develop immune system alterations that result in reduced respiratory burst function and cytokine production despite upregulation of TLR‐4.
Collapse
Affiliation(s)
- D Hoffman
- The Comparative Internal Medicine Laboratory, University of Missouri College of Veterinary Medicine, Columbia, MO
| | - J Amorim
- The Comparative Internal Medicine Laboratory, University of Missouri College of Veterinary Medicine, Columbia, MO
| | - A DeClue
- The Comparative Internal Medicine Laboratory, University of Missouri College of Veterinary Medicine, Columbia, MO
| |
Collapse
|
16
|
Hoffman D, Gastin P, Robertson S, Bourdon P, Douglas A. Anthropometric and physical fitness comparisons between Australian and Qatari male sport school athletes. J Sci Med Sport 2017. [DOI: 10.1016/j.jsams.2017.09.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Ber R, Hoffman D, Hoffman C, Polat A, Derazne E, Mayer A, Katorza E. Volume of Structures in the Fetal Brain Measured with a New Semiautomated Method. AJNR Am J Neuroradiol 2017; 38:2193-2198. [PMID: 28838909 DOI: 10.3174/ajnr.a5349] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2017] [Accepted: 06/12/2017] [Indexed: 12/27/2022]
Abstract
BACKGROUND AND PURPOSE Measuring the volume of fetal brain structures is challenging due to fetal motion, low resolution, and artifacts caused by maternal tissue. Our aim was to introduce a new, simple, Matlab-based semiautomated method to measure the volume of structures in the fetal brain and present normal volumetric curves of the structures measured. MATERIALS AND METHODS The volume of the supratentorial brain, left and right hemispheres, cerebellum, and left and right eyeballs was measured retrospectively by the new semiautomated method in MR imaging examinations of 94 healthy fetuses. Four volume ratios were calculated. Interobserver agreement was calculated with the intraclass correlation coefficient, and a Bland-Altman plot was drawn for comparison of manual and semiautomated method measurements of the supratentorial brain. RESULTS We present normal volumetric curves and normal percentile values of the structures measured according to gestational age and of the ratios between the cerebellum and the supratentorial brain volume and the total eyeball and the supratentorial brain volume. Interobserver agreement was good or excellent for all structures measured. The Bland-Altman plot between manual and semiautomated measurements showed a maximal relative difference of 7.84%. CONCLUSIONS We present a technologically simple, reproducible method that can be applied prospectively and retrospectively on any MR imaging protocol, and we present normal volumetric curves measured. The method shows results like manual measurements while being less time-consuming and user-dependent. By applying this method on different cranial and extracranial structures, anatomic and pathologic, we believe that fetal volumetry can turn from a research tool into a practical clinical one.
Collapse
Affiliation(s)
- R Ber
- From the Departments of Obstetrics and Gynecology (R.B., D.H., A.P., E.K.)
| | - D Hoffman
- From the Departments of Obstetrics and Gynecology (R.B., D.H., A.P., E.K.)
| | - C Hoffman
- Diagnostic Imaging (C.H., A.M.), Chaim Sheba Medical Center, Tel Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- Sackler Faculty of Medicine (C.H., E.D.), Tel-Aviv University, Tel-Aviv, Israel
| | - A Polat
- From the Departments of Obstetrics and Gynecology (R.B., D.H., A.P., E.K.)
| | - E Derazne
- Sackler Faculty of Medicine (C.H., E.D.), Tel-Aviv University, Tel-Aviv, Israel
| | - A Mayer
- Diagnostic Imaging (C.H., A.M.), Chaim Sheba Medical Center, Tel Hashomer, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - E Katorza
- From the Departments of Obstetrics and Gynecology (R.B., D.H., A.P., E.K.)
| |
Collapse
|
18
|
Watson J, Bhat R, Izzo J, Blumenthal J, Hoffman D, Descallar E, Houser C, Booker E. 325 Telemedicine Model of Physician Intake Decreases Door-to-Provider Time. Ann Emerg Med 2017. [DOI: 10.1016/j.annemergmed.2017.07.396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
19
|
Izzo J, Bhat R, Blumenthal J, Hoffman D, Watson J, Booker E. 323 Diagnostic Accuracy of a Rapid Telemedicine Encounter in the Emergency Department. Ann Emerg Med 2017. [DOI: 10.1016/j.annemergmed.2017.07.394] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Hawryluk RJ, Mueller D, Hosea J, Barnes CW, Beer M, Bell MG, Bell R, Biglari H, Bitter M, Boivin R, Bretz NL, Budny R, Bush CE, Chen L, Cheng CZ, Cowley S, Dairow DS, Efthimion PC, Fonck RJ, Fredrickson E, Furth HP, Greene G, Grek B, Grisham LR, Hammett G, Heidbrink W, Hill KW, Hoffman D, Hulse RA, Hsuan H, Janos A, Jassby DL, Jobes FC, Johnson DW, Johnson LC, Kamperschroer J, Kesner J, Phillips CK, Kilpatrick SJ, Kugel H, LaMarche PH, LeBlanc B, Manos DM, Mansfield DK, Marmar ES, Mazzucato E, McCarthy MP, Machuzak J, Mauel M, McCune D, McGuire KM, Medley SS, Monticello DR, Mikkelsen D, Nagayama Y, Navratil GA, Nazikian R, Owens DK, Park H, Park W, Paul S, Perkins F, Pitcher S, Rasmussen D, Redi MH, Rewoldt G, Roberts D, Roquemore AL, Sabbagh S, Schilling G, Schivell J, Schmidt GL, Scott SD, Snipes J, Stevens J, Stratton BC, Strachan JD, Stodiek W, Synakowski E, Tang W, Taylor G, Terry J, Timberlake JR, Ulrickson HH, Towner M, von Goeler S, Wieland R, Wilson JR, Wong KL, Woskov P, Yamada M, Young KM, Zamstorff MC, Zweben SJ. Status and Plans for TFTR. ACTA ACUST UNITED AC 2017. [DOI: 10.13182/fst92-a29907] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. J. Hawryluk
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. Mueller
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Hosea
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - M. Beer
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. G. Bell
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Bell
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Biglari
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. Bitter
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Boivin
- Massachusetts Institute of Technology, Cambridge, MA
| | - N. L. Bretz
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Budny
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - C. E. Bush
- Oak Ridge National Laboratory, Oak Ridge, TN
| | - L. Chen
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - C. Z. Cheng
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. Cowley
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. S. Dairow
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - P. C. Efthimion
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - E. Fredrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. P. Furth
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Greene
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - B. Grek
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - L. R. Grisham
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Hammett
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - K. W. Hill
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. Hoffman
- Oak Ridge National Laboratory, Oak Ridge, TN
| | - R. A. Hulse
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Hsuan
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - A. Janos
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. L. Jassby
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - F. C. Jobes
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. W. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - L. C. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Kamperschroer
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Kesner
- Massachusetts Institute of Technology, Cambridge, MA
| | - C. K. Phillips
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. J. Kilpatrick
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Kugel
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - P. H. LaMarche
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - B. LeBlanc
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. M. Manos
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. K. Mansfield
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - E. S. Marmar
- Massachusetts Institute of Technology, Cambridge, MA
| | - E. Mazzucato
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. P. McCarthy
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Machuzak
- Massachusetts Institute of Technology, Cambridge, MA
| | - M. Mauel
- Columbia University, New York, NY
| | - D.C. McCune
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - K. M. McGuire
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. S. Medley
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. R. Monticello
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. Mikkelsen
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | | | - R. Nazikian
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. K. Owens
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Park
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - W. Park
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. Paul
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - F. Perkins
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. Pitcher
- Canadian Fusion Fuels Technology Project, Toronto, Canada
| | | | - M. H. Redi
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Rewoldt
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - A. L. Roquemore
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - G. Schilling
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Schivell
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. L. Schmidt
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. D. Scott
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Snipes
- Massachusetts Institute of Technology, Cambridge, MA
| | - J. Stevens
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - B. C. Stratton
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. D. Strachan
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - W. Stodiek
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - E. Synakowski
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - W. Tang
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Taylor
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Terry
- Massachusetts Institute of Technology, Cambridge, MA
| | - J. R. Timberlake
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. H. Ulrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. Towner
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. von Goeler
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Wieland
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. R. Wilson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - K. L. Wong
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - P. Woskov
- Massachusetts Institute of Technology, Cambridge, MA
| | - M. Yamada
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - K. M. Young
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. C. Zamstorff
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. J. Zweben
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| |
Collapse
|
21
|
Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L, Erez N. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene 2017; 36:4457-4468. [PMID: 28368410 PMCID: PMC5507301 DOI: 10.1038/onc.2017.65] [Citation(s) in RCA: 180] [Impact Index Per Article: 25.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Revised: 02/02/2017] [Accepted: 02/05/2017] [Indexed: 12/11/2022]
Abstract
Cancer-Associated Fibroblasts (CAFs) are the most prominent stromal cell type in breast tumors. CAFs promote tumor growth and metastasis by multiple mechanisms, including by mediating tumor-promoting inflammation. Immune modulation in the tumor microenvironment plays a central role in determining disease outcome. However, the functional interactions of CAFs with immune cells are largely unknown. Here we report a novel signaling axis between fibroblasts, cancer cells and immune cells in breast tumors that drives an immunosuppressive microenvironment, mediated by CAF-derived Chi3L1. We demonstrate that Chi3L1 is highly upregulated in CAFs isolated from mammary tumors and pulmonary metastases of transgenic mice, and in the stroma of human breast carcinomas. Genetic ablation of Chi3L1 in fibroblasts in vivo attenuated tumor growth, macrophage recruitment and reprogramming to an M2-like phenotype, enhanced tumor infiltration by CD8+ and CD4+ T cells and promoted a Th1 phenotype. These results indicate that CAF-derived Chi3L1 promotes tumor growth and shifts the balance of the immune milieu towards type 2 immunity. Taken together, our findings implicate fibroblast-derived Chi3L1 as a novel key player in the complex reciprocal interactions of stromal cells that facilitate tumor progression and metastasis, and suggest that targeting Chi3L1 may be clinically beneficial in breast cancer.
Collapse
Affiliation(s)
- N Cohen
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - O Shani
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Y Raz
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Obstetrics and Gynecology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Y Sharon
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - D Hoffman
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L Abramovitz
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - N Erez
- Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
22
|
Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene 2017; 36:3749-3759. [PMID: 28218903 PMCID: PMC5491354 DOI: 10.1038/onc.2017.1] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Revised: 12/20/2016] [Accepted: 12/22/2016] [Indexed: 02/07/2023]
Abstract
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment. We confirmed increased tumor-associated macrophages in bevacizumab-resistant glioblastoma patient specimens and two novel glioblastoma xenograft models of bevacizumab resistance. Microarray analysis suggested downregulated macrophage migration inhibitory factor (MIF) to be the most pertinent mediator of increased macrophages. Bevacizumab-resistant patient glioblastomas and both novel xenograft models of resistance had less MIF than bevacizumab-naive tumors, and harbored more M2/protumoral macrophages that specifically localized to the tumor edge. Xenografts expressing MIF-shRNA grew more rapidly with greater angiogenesis and had macrophages localizing to the tumor edge which were more prevalent and proliferative, and displayed M2 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the opposite changes. Bone marrow-derived macrophage were polarized to an M2 phenotype in the presence of condition-media derived from bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1 polarization. Media from macrophages exposed to bevacizumab-resistant tumor cell conditioned media increased glioma cell proliferation compared with media from macrophages exposed to bevacizumab-responsive tumor cell media, suggesting that macrophage polarization in bevacizumab-resistant xenografts is the source of their aggressive biology and results from a secreted factor. Two mechanisms of bevacizumab-induced MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would downregulate MIF. Site-directed biopsies revealed enriched MIF and VEGF at the enhancing edge in bevacizumab-naive patients. This MIF enrichment was lost in bevacizumab-resistant glioblastomas, driving a tumor edge M1-to-M2 transition. Thus, bevacizumab resistance is driven by reduced MIF at the tumor edge causing proliferative expansion of M2 macrophages, which in turn promotes tumor growth.
Collapse
Affiliation(s)
- B A Castro
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - P Flanigan
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - A Jahangiri
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - D Hoffman
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - W Chen
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - R Kuang
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - M De Lay
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - G Yagnik
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - J R Wagner
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - S Mascharak
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - M Sidorov
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - S Shrivastav
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - G Kohanbash
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - H Okada
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - M K Aghi
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| |
Collapse
|
23
|
Shomali M, Cheng J, Koundinya M, Weinstein M, Malkova N, Sun F, Hebert A, Cindachao M, Hoffman D, McManus J, Levit M, Pollard J, Vincent S, Besret L, Adrian F, Winter C, El-Ahmad Y, Halley F, Hsu K, Lager J, Garcia-Echeverria C, Bouaboula M. Abstract P3-04-05: Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-04-05] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogen receptor positive (ER+) breast cancer accounts for 70% of all breast cancers and is primarily treated with endocrine therapy. Approximately 40% of patients on endocrine therapy will become resistant via a number of mechanisms. There is evidence that in many cases ER continues to play a central role, including mutations in ER leading to a constitutively active receptor. Estrogen receptor degraders like fulvestrant are effective in shutting down ER signaling; however, poor pharmaceutical properties limit fulvestrant clinical activity and prevent it from achieving maximum receptor blockade.
We describe the discovery of SAR439859, a novel, orally bioavailable SERD that is a potent antagonist and degrader of ER both in vitro and in vivo. SAR439859 has robust activity in multiple ER+ breast cancer cell lines including cells that are resistant to tamoxifen as well as cell lines harboring ER mutants. Across a large panel of ER+ cells, SAR439859 demonstrated broad and superior ER degradation activity than most SERDs undergoing clinical testing. This leads to a profound inhibition of ER signaling, better inhibition of cell growth and results in improved in vivo efficacy. SAR439859 demonstrated tumor regression in all ER+ BC models including MCF7-ESR1 mutant-Y537S model, as well as patient-derived xenograft model that is resistant to endocrine therapies. Furthermore, SAR439859 displays limited cross-resistance with other class of SERDs.
Taken together, these results suggest that SAR439859 would be of therapeutic benefit in metastatic BC setting for patients harboring wild type or mutant ER. SAR439859 is being advanced toward the clinic.
Citation Format: Shomali M, Cheng J, Koundinya M, Weinstein M, Malkova N, Sun F, Hebert A, Cindachao M, Hoffman D, McManus J, Levit M, Pollard J, Vincent S, Besret L, Adrian F, Winter C, El-Ahmad Y, Halley F, Hsu K, Lager J, Garcia-Echeverria C, Bouaboula M. Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-05.
Collapse
Affiliation(s)
- M Shomali
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - J Cheng
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - M Koundinya
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - M Weinstein
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - N Malkova
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - F Sun
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - A Hebert
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - M Cindachao
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - D Hoffman
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - J McManus
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - M Levit
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - J Pollard
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - S Vincent
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - L Besret
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - F Adrian
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - C Winter
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - Y El-Ahmad
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - F Halley
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - K Hsu
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | - J Lager
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| | | | - M Bouaboula
- Sanofi, Cambridge, MA; Sanofi, Vitry-Sur-Seine, France
| |
Collapse
|
24
|
Dyer B, Zhao X, Hoffman D, Kahn L, Hodges M, Hayes J, Michaud A, Hess C, Kumaran Nair C, Fragoso R, Valicenti R, Mayadev J. Mortality in Radiation Oncology: A 16-Year Departmental Review. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, Iqbal K, Lenz O, Asif A, Nahar N, Leclerq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida Suarez M, Busse JC, Esquenazi M, Esquenazi A, Garcia Mayol L, Garcia Estrada H. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2016; 14:890-5. [PMID: 16335581 DOI: 10.1191/0961203305lu2238oa] [Citation(s) in RCA: 128] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of this study was to identify the factors associated with important clinical outcomes in a case-control study of 213 patients with lupus nephritis. Included were 47% Hispanics, 44% African Americans and 9% Caucasians with a mean age of 28 years. Fifty-four (25%) patients reached the primary composite outcome of doubling serum creatinine, end-stage renal disease or death during a mean follow-up of 37 months. Thirty-four percent African Americans, 20% Hispanics and 10% Caucasians reached the primary composite outcome ( P < 0.05). Patients reaching the composite outcome had predominantly proliferative lupus nephritis (WHO classes: 30% III, 32% IV, 18% V and 5% II, P < 0.025) with higher activity index score (7 ± 6 versus 5 ± 5, P<0.05), chronicity index (CI) score (4 ± 3 versus 2 ± 2 unit, P<0.025), higher baseline mean arterial pressure (MAP) (111 ± 21 versus 102 ± 14 mmHg, P<0.025) and serum creatinine (1.9 ± 1.3 versus 1.3 ± 1.0 mg/dL, P<0.025), but lower baseline hematocrit (29 ± 6 versus 31 + 5%, P<0.025) and complement C3 (54 ± 26 versus 65 + 33 mg/dL, P<0.025) compared to controls. More patients reaching the composite outcome had nephrotic range proteinuria compared to controls (74% versus 56%, P<0.025). By multivariate analysis, CI (hazard ratio [95% CI] 1.18 [1.07-1.30] per point), MAP (HR 1.02 [1.00-1.03] per mmHg), and baseline serum creatinine (HR 1.26 [1.04-1.54] per mg/dL) were independently associated with the composite outcome. We concluded that hypertension and elevated serum creatinine at the time of the kidney biopsy as well as a high CI are associated with an increased the risk for chronic renal failure or death in patients with lupus nephritis.
Collapse
Affiliation(s)
- G Contreras
- Acute Dialysis Unit Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hoffman D, Dyer B, Kumaran Nair C, Katuri Y, Rong Y, Benedict S. SU-F-T-326: Diode Array Transmission Detector Systems Evaluation. Med Phys 2016. [DOI: 10.1118/1.4956511] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
27
|
Hoffman D, Nair CK, Wright C, Yamamoto T, Mayadev J, Valicenti R, Benedict S, Markham J, Rong Y. SU-F-T-433: Evaluation of a New Dose Mimicking Application for Clinical Flexibility and Reliability. Med Phys 2016. [DOI: 10.1118/1.4956618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
28
|
Hoffman D, Dyer B, Kumaran Nair C, Stern R, Benedict S, Davis UC. SU-F-T-471: Simulated External Beam Delivery Errors Detection with a Large Area Ion Chamber Transmission Detector. Med Phys 2016. [DOI: 10.1118/1.4956656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
Kumaran Nair C, Hoffman D, Wright C, Yamamoto T, Rao S, Benedict S, Markham J, Rong Y. SU-F-T-346: Dose Mimicking Inverse Planning Based On Helical Delivery Treatment Plans for Head and Neck Patients. Med Phys 2016. [DOI: 10.1118/1.4956531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
30
|
Michaud A, Hoffman D, Daly M, Semon S, Benedict S. Optimization of On-board 4D Cone Beam Computed Tomography for Pretreatment Patient Positioning Verification, Tumor Localization, and Motion Management Assessment. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.2037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Hoffman D, Chung E, Hess C, Stern R, Benedict S. Online Quality Assurance of External Beam Radiation Therapy With an Integrated Quality Monitoring System. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.2035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Hoffman D, Chung E, Hess C, Stern R, Benedict S. SU-E-T-571: Newly Emerging Integrated Transmission Detector Systems Provide Online Quality Assurance of External Beam Radiation Therapy. Med Phys 2015. [DOI: 10.1118/1.4924933] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Toffart AC, Duruisseaux M, Nagy-Mignotte H, Sakhri L, Brichon PY, Villa J, Hoffman D, Guillem P, Timsit JF, Moro-Sibilot D. Cancers bronchiques oligométastatiques : une survie proche des maladies localement avancées. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Prates R, Jordan A, Rosen G, DiMattina M, Chen S, Tan SL, Hoffman D, Jaroudi S, Konstantinidis M. Usage of karyomapping for preimplantation genetic diagnosis (PGD) of complex single gene disorders (sgds). Fertil Steril 2014. [DOI: 10.1016/j.fertnstert.2014.07.595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
35
|
Bristow S, Kumar N, Rodriguez S, Bisignano A, Hoffman D. The role of classical and non-classical congenital adrenal hyperplasia (CAH) in infertilty: an analysis of 2000 clinical samples. Fertil Steril 2014. [DOI: 10.1016/j.fertnstert.2014.07.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Posadas E, Tighiouart M, Lu Y, Di Vizio D, Hoffman D, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng H, Chung L, Figlin R. A Translational Phase 2 Study of Cabozantinib in Men with Metastatic Castration Resistant Prostate Cancer with Visceral Metastases with Characterization of Circulating Tumor Cells and Large Oncosomes. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
|
38
|
O'Donoughue LS, Sorrells ME, Tanksley SD, Autrique E, Deynze AV, Kianian SF, Phillips RL, Wu B, Rines HW, Rayapati PJ, Lee M, Penner GA, Fedak G, Molnar SJ, Hoffman D, Salas CA. A molecular linkage map of cultivated oat. Genome 2012; 38:368-80. [PMID: 18470176 DOI: 10.1139/g95-048] [Citation(s) in RCA: 111] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A molecular linkage map of cultivated oat composed of 561 loci has been developed using 71 recombinant inbred lines from a cross between Avena byzantina cv. Kanota and A. sativa cv. Ogle. The loci are mainly restriction fragment length polymorphisms detected by oat cDNA clones from leaf, endosperm, and root tissue, as well as by barley leaf cDNA clones. The loci form 38 linkage groups ranging in size from 0.0 to 122.1 cM (mean, 39 cM) and consist of 2-51 loci each (mean, 14). Twenty-nine loci remain unlinked. The current map size is 1482 cM and the total size, on the basis of the number of unlinked loci, is estimated to be 2932.0 cM. This indicates that this map covers at least 50% of the cultivated oat genome. Comparisons with an A-genome diploid oat map and between linkage groups exhibiting homoeology to each other indicate that several major chromosomal rearrangements exist in cultivated oat. This map provides a tool for marker-assisted selection, quantitative trait loci analyses, and studies of genome organization in oat.
Collapse
|
39
|
Camidge D, Doebele R, Ballas M, Jahan T, Haigentz M, Hoffman D, Spicer J, West H, Yurasov S, Mita A. Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33884-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
40
|
Hoffman D, Dyleram D. Comparison of the Millard and Fisher technique for closure of the unilateral cleft lip. Int J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.ijom.2011.07.1061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
41
|
Hoffman D, Panetta T. Treatment of TMJ ankylosis utilizing preoperative CT angiography, surgical navigation, and intraoperative ebolization. Int J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.ijom.2011.07.1042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Kim J, Shibata T, Hoffman D, Banks M. Assessing vergence-accommodation conflict as a source of discomfort in stereo displays. J Vis 2011. [DOI: 10.1167/11.11.324] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
43
|
Gualtieri M, Hoffman D, Barrionuevo M, Christie D, Mouhayar Y, Ory S. The effects of cabergoline on ovarian hyperstimulation syndrome (OHSS) and pregnancy outcomes on in vitro fertilization (IVF) patients. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.994] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Bouba I, Bountouri C, Dounousi E, Kiatou V, Georgiou I, Chatzidakis S, Kotzadamis N, Tsakiris D, Siamopoulos K, Dimas G, Iliadis F, Tegos T, Makedou K, Didangelos T, Pitsalidis C, Chatziapostolou A, Makedou A, Baloyannis S, Grekas D, Li O, Bobkova I, Tchebotareva N, Kozlovskaya L, Varshavskiy V, Mydlik M, Derzsiova K, Bohu B, Clapp E, Kosmadakis G, Smith A, Viana J, Shirreffs S, Maughan R, Feehally J, Bevington A, Ando M, Yanagisawa N, Hara M, Tsuchiya K, Nitta K, Chen CH, Wang CL, Huang JW, Hung KY, Tsai TJ, Gadalean F, Gluhovschi G, Kaycsa A, Trandafirescu V, Petrica L, Velciov S, Bozdog G, Gluhovschi C, Bob F, Solberg Eikrem O, Hope Jaeger-Hoie E, Hausken T, Svarstad E, de Goeij M, Liem M, de Jager D, Voormolen N, Sijpkens Y, Boeschoten E, Dekker F, Grootendorst D, Halbesma N, Moran AM, Kenny E, Ward F, Dunne OM, Holian J, Watson AJ, Saginova E, Gallyamov M, Severova M, Surkova O, Fomin V, Topchii I, Kirienko A, Schenyavskaya E, Efimova N, Bondar T, Lesovaja A, Gama Axelsson T, Barany P, Heimburger O, Lindholm B, Stenvinkel P, Qureshi AR, Bal Z, Erkmen Uyar M, Ahmed N, Tutal E, Sezer S, Labrador PJ, Gonzalez Castillo PM, Silva Junior GB, Liborio AB, Lopes Filho AS, Figueiredo Filho AC, Vieira APF, Couto Bem AX, Guedes ALMO, Costa CMBE, Holanda de Souza J, Daher EF, Donadio C, Kanaki A, Tognotti D, Donadio E, Reznik E, Guschina V, Volinkina V, Gendlin G, Storozhakov G, Capusa C, Stancu S, Badulescu M, Ilyes A, Anghel C, Mircescu G, Yonemoto S, Fujii N, Hamano T, Okuno A, Soda T, Yamanaka K, Hirai T, Nishimura K, Ichikawa Y, Boudville N, Kemp A, Champion de Crespigny P, Fassett R, Healy H, Mangos G, Moody H, Pedagogos E, Waugh D, Kirkland G, Kay T, Hoffman D, Abaterusso C, Branco C, Thomaseth K, Graziani MS, Lupo A, Chaudhry M, Lok C, Kudo K, Konta T, Takasaki S, Degawa N, Kubota I, Nykula T, Moyseyenko V, Topchii A, Nanami K, Yoshiharu T, Hiroshi Y, Miyuki M, Masayuki N, Sotila GG, Rugina S, Tuta L, Dumitru I, Cernat R, Sotila GG, Rugina S, Dumitru I, Cernat R, Rugina C, Kim IY, Lee SB, Choi BK, Son J, Lee HS, Lee N, Rhee H, Song SH, Seong EY, Kwak IS. Progression & risk factors CKD 1-5 (2). Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Blauwblomme T, Minotti L, Hoffman D, Chabardes S, Kahane P. Rôle pronostique de l’implication de l’insula dans les épilepsies temporales : une étude SEEG. Neurochirurgie 2010. [DOI: 10.1016/j.neuchi.2010.10.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
|
47
|
Nilson C, Hoffman D. The effects of scene inversion and negation on change detection. J Vis 2010. [DOI: 10.1167/2.7.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
48
|
Huang EK, Nguyen BM, Hoffman D, Delaunay PY, Razeghi M. Inductively coupled plasma etching and processing techniques for type-II InAs/GaSb superlattices infrared detectors toward high fill factor focal plane arrays. ACTA ACUST UNITED AC 2009. [DOI: 10.1117/12.810030] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
49
|
Gourraud PA, Hoffman D, Cambon-Thomsen A, Feolo M. 14th International HLA and Immunogenetics Workshop: report on mapping microsatellite markers in the major histocompatibility complex region. ACTA ACUST UNITED AC 2007; 69 Suppl 1:206-9. [PMID: 17445202 DOI: 10.1111/j.1399-0039.2006.00770.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
This paper describes the use of the program e-pcr to localize 687 known major histocompatability complex (MHC) microsatellite primer pairs to their sequence positions in several genomic assemblies across the MHC region. The sequences used were the Sequences of Sanger Institute's MHC Haplotype Project: COX, PGF, QBL, as well as the Celera, and Reference (PGF across extended MHC) sequences from the NCBI genomic build 36. More than 95% (664/687) of the markers mapped unambiguously to the Reference assembly sequence. All primer pairs used in this analysis, and those were previously unknown to UniSTS, have now been assigned permanent public UniSTS identifiers. Mapping and descriptive data for each primer pair are available at the publicly accessible dbMHC microsatellite resource: http://www.ncbi.nlm.nih.gov/projects/mhc/xslcgi.fcgi?cmd=mssearch.
Collapse
|
50
|
Steenkiste A, Valdes AM, Feolo M, Hoffman D, Concannon P, Noble J, Schoch G, Hansen J, Helmberg W, Dorman JS, Thomson G, Pugliese A. 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes. ACTA ACUST UNITED AC 2007; 69 Suppl 1:214-25. [PMID: 17445204 DOI: 10.1111/j.1399-0039.2006.00772.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The type 1 diabetes (T1D) component of the 13th International Histocompatibility Workshop (IHW) obtained microsatellite (msat) and human leukocyte antigen (HLA)-DR/DQ data on case/control and family samples through an international collaboration. The aim was to detect the effects of susceptibility loci on the HLA complex independent of the primary determinants in the class II region (HLA-DR/DQ). As part of the activity of the 14th International HLA and Immunogenetics Workshop (14th IHIWS), a T1D workshop was held to present analyses of the 13th IHW data and to discuss the current status of knowledge about the genetics of T1D. These data are now available online through dbMHC, a web-based resource established by the National Center for Biotechnology. Continuing work since the 13th IHW has resulted in published work showing heterogeneity of DR3 haplotypes in data sets from the 13th IHW and Human Biological Data Interchange (HBDI). In addition, we identified markers that define DRB1*1501 DQB1*0602 haplotypes conferring reduced protection from diabetes in a Swedish 13th IHW data set. Further analyses of the 13th IHW data set not only showed some significant results but also demonstrated extensive heterogeneity reminiscent of non-HLA genes. The haplotype analysis in HBDI families identified two msats with significant effects on susceptibility and statistically significant age of onset effects at class III markers that are not because of linkage disequilibrium, with class I alleles known to affect age of onset. The above studies underscore the importance of refining our understanding of susceptibility associated with genes in the HLA complex.
Collapse
Affiliation(s)
- A Steenkiste
- Department of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|